UP!

AET $212.7   View long term graphs

Aetna Inc.
Type
Public
Traded as NYSE: AET
S&P 500 Component
Industry Managed health care
Founded May 28, 1853; 164 years ago (1853-05-28) (as Aetna Life Insurance Company)
Founder Eliphalet Adams Bulkeley
Headquarters 151 Farmington Ave, Hartford, Connecticut, 06105 U.S.
Area served
United States
Key people
Mark T. Bertolini
(Chairman and CEO)
Karen S. Lynch
(President)
Products Healthcare plans
Revenue Increase $ 63.175 billion (FY 2016)
Operating income
Increase $ 2.917 billion (FY 2016)
Net income
Decrease $ 2.271 billion (FY 2016)
Total assets Increase $ 2.271 billion (FY 2016)
Total equity Increase $ 17.943 billion (FY 2016)
Number of employees
49,500 (FY 2016)
Website www.aetna.com

Aetna Inc. (/ˈɛtnə/; stylized as ætna) is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

In June 2017, the company announced plans to move its headquarters to New York City in late 2018.

Aetna offers health care, dental, pharmacy, group life, disability, and long-term care insurance and employee benefits, primarily through employer-paid (fully or partly) insurance and benefit programs, and through Medicare. Membership numbers: (as of September 30, 2016)

Aetna has spent more than $2.0 million in 2009 on lobbying. The company spent $809,793 between January 2009 and the end of March 2009—up 41 percent from the same period in 2008. Aetna's campaign contributions include more than $110,000 to US Senator Joe Lieberman (ID-CT) in 2009. From 2005 through 2009, Aetna contributed $56,250 to Senator Max Baucus (D-MT), chairman of the Senate Finance Committee, making Aetna the senator's seventh highest contributor over that time period.

In the California Health Care Quality Report Card 2011 Edition, Aetna received 2 out of 4 stars in Meeting National Standards of Care and 1 out of 4 in Members Rate Their HMO. In the California Health Care Quality Report Card 2010 Edition, Aetna received 3 out of 4 stars in both Meeting National Standards of Care and How Members Rate Their HMO, for a rating of "Good" (out of "Poor, " "Fair, " "Good, " or "Excellent").

As of 2017 Aetna shares are mainly held by institutional investors (BlackRock, The Vanguard Group, State Street Corporation, T. Rowe Price, Capital Group Companies and others)

Aetna is the direct descendant of Aetna (Fire) Insurance Company, of Hartford, Connecticut. The name was meant to invoke Mount Etna, at the time Europe's most active volcano.

In June 2012, Aetna and Inova Health System announced a joint venture creating a new health insurance company, Innovation Health.

On July 3, 2015, Aetna announced that it planned to acquire Humana for US$37,000,000,000 in cash and stock, or US$230 a share. Aetna and Humana shareholders would have owned 74% and 26% of the new combined company. The acquisition was subject to United States government approval and was expected to close in late 2016.

On January 23, 2017, a federal judge blocked Aetna's merger with Humana, saying it would leave senior citizens with fewer options for Medicare coverage. On February 14, 2017, Aetna Inc. and Humana Inc. officially quashed a $34 billion merger agreement, after judges ruled against the merger for a second time.

On June 29, 2017, Aetna announced the company would be moving their main offices to New York City after being headquartered in Hartford since 1819. The moved will be completed in late 2018.

In 2000 Deadria Farmer-Paellmann, head of the nonprofit Restitution Study Group of Hoboken, New Jersey, disclosed that from approximately 1853 to approximately 1860 Aetna had issued life insurance policies to slaveowners covering the lives of their slaves.

Aetna acknowledged that concrete evidence exists for Aetna issuing coverage for the lives of slaves and released a public apology.

In 2002, Farmer-Paellmann brought suit against Aetna and two other companies in federal court asking for reparations for the descendants of slaves. The lawsuit said Aetna, CSX and Fleet were "unjustly enriched" by "a system that enslaved, tortured, starved and exploited human beings." It argued that African-Americans are still suffering the effects of 2½ centuries of enslavement followed by more than a century of institutionalized racism. The complaint blamed slavery for present-day disparities between blacks and whites in income, education, literacy, health, life expectancy and crime.

This suit was denied, and the denial largely upheld on appeal.

In 2006, Farmer-Paellmann announced a nationwide boycott of Aetna over the issue of reparations for its policies covering slaves. Aetna stated that its commitment to diversity in the workplace and its investment of over 36 million dollars in such areas as education, health, economic development, community partnerships, and minority-owned business initiatives in the African-American community are more effective at aiding descendants of slaves and African-Americans in general than making restitutions for Aetna's life insurance policies on slaves.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q1 2019 2019-04-30 Future report Set alerts
Q4 2018 2019-01-28 Future report Set alerts
Q3 2018 2018-10-30 2.96 3.03
Q2 2018 2018-08-02 3.43 3.67
Q1 2018 2018-05-01 3.19 3.67
Q4 2017 2018-01-30 1.25 0.74
Q3 2017 2017-10-31 2.45 2.52
Q2 2017 2017-08-03 3.42 3.60
Q1 2017 2017-05-02 2.71 -1.11
Q4 2016 2017-01-31 1.63 0.39

Ratings

2016-07-10 Reiterated Rating Credit Suisse Group AG Neutral to Hold
2016-06-29 Reiterated Rating Credit Suisse Hold $120.00
2016-06-29 Reiterated Rating Credit Suisse Group AG Hold $120.00
2016-06-28 Initiated Coverage Wolfe Research Outperform $154.00
2016-06-21 Reiterated Rating Leerink Swann Outperform
2016-06-16 Initiated Coverage Sanford C. Bernstein Outperform $142.00
2016-06-14 Reiterated Rating Morgan Stanley Buy
2016-06-02 Reiterated Rating Wells Fargo Buy
2016-06-02 Reiterated Rating Wells Fargo & Co. Buy
2016-05-16 Reiterated Rating Sterne Agee CRT Buy
2016-04-30 Reiterated Rating Morgan Stanley Buy
2016-04-29 Reiterated Rating FBR & Co. Hold $135.00
2016-04-29 Boost Price Target RBC Capital Outperform $140.00 to $144.00
2016-04-29 Reiterated Rating FBR & Co Hold $135.00
2016-04-29 Boost Price Target Royal Bank Of Canada Outperform $140.00 to $144.00
2016-04-08 Initiated Coverage Cleveland Research Neutral $120.00
2016-04-05 Reiterated Rating Leerink Swann Outperform
2016-04-05 Reiterated Rating Cowen and Company Outperform
2016-02-19 Reiterated Rating Wells Fargo Buy
2016-02-03 Boost Price Target BMO Capital Markets Outperform $128.00 to $129.00
2016-02-02 Reiterated Rating FBR & Co. Market Perform $135.00
2016-02-02 Lower Price Target Jefferies Group Hold $122.00 to $118.00
2016-02-02 Lower Price Target Wedbush Neutral $130.00 to $120.00
2016-02-02 Reiterated Rating Oppenheimer Market Perform
2016-02-02 Lower Price Target RBC Capital Outperform $142.00 to $140.00
2016-02-02 Reiterated Rating Cantor Fitzgerald Buy $140.00
2016-02-02 Reiterated Rating Oppenheimer Holdings Inc. Market Perform
2016-01-08 Downgrade Jefferies Group Buy to Hold $135.00 to $122.00
2015-12-17 Reiterated Rating Credit Suisse Hold
2015-12-16 Initiated Coverage Credit Suisse Neutral $111.00
2015-11-23 Reiterated Rating Leerink Swann Outperform
2015-10-30 Lower Price Target RBC Capital $162.00 to $146.00
2015-10-30 Lower Price Target JPMorgan Chase & Co. $144.00 to $141.00
2015-10-30 Reiterated Rating Leerink Swann Buy $160.00
2015-09-18 Upgrade Cantor Fitzgerald Hold to Buy $100.00 to $140.00
2015-09-16 Initiated Coverage JPMorgan Chase & Co. Overweight $144.00
2015-09-08 Upgrade RBC Capital Sector Perform to Outperform $159.00 to $162.00
2015-08-13 Reiterated Rating Jefferies Group Buy $135.00
2015-08-05 Reiterated Rating Oppenheimer Hold
2015-08-04 Reiterated Rating Leerink Swann Buy
2015-08-04 Reiterated Rating Sterne Agee CRT Buy $134.00
2015-08-04 Reiterated Rating Susquehanna Buy $135.00
2015-07-30 Upgrade Bank of America Neutral to Buy $132.00
2015-07-30 Upgrade Bank of America Corp. Neutral to Buy $132.00
2015-07-08 Reiterated Rating Barclays Buy
2015-07-08 Reiterated Rating Barclays PLC Buy
2015-07-07 Reiterated Rating S&P Equity Research Strong-Buy $150.00
2015-07-06 Reiterated Rating Cowen and Company Buy $145.00
2015-07-06 Boost Price Target Barclays Overweight $125.00 to $152.00
2015-07-06 Boost Price Target Leerink Swann Outperform $150.00 to $160.00
2015-07-06 Downgrade FBR & Co. Outperform to Market Perform $120.00 to $130.00
2015-06-28 Reiterated Rating Leerink Swann Buy
2015-06-26 Boost Price Target Leerink Swann Outperform $145.00 to $150.00
2015-06-24 Initiated Coverage RBC Capital Sector Perform $159.00
2015-06-17 Reiterated Rating Deutsche Bank Buy $122.00 to $135.00
2015-06-17 Reiterated Rating Leerink Swann Outperform to Outperform $135.00 to $145.00
2015-06-17 Reiterated Rating Deutsche Bank AG Buy $122.00 to $135.00
2015-05-23 Reiterated Rating Leerink Swann Outperform $130.00 to $135.00
2015-05-13 Reiterated Rating Deutsche Bank Buy $122.00
2015-05-12 Boost Price Target Leerink Swann Outperform $130.00 to $135.00
2015-05-04 Reiterated Rating BMO Capital Markets Outperform $119.00 to $122.00
2015-04-29 Set Price Target Leerink Swann Buy $125.00 to $130.00
2015-04-29 Set Price Target Barclays Buy $122.00 to $125.00
2015-04-29 Boost Price Target Argus Buy $115.00 to $130.00
2015-03-20 Set Price Target Barclays Buy $119.00 to $122.00
2015-03-19 Upgrade Sterne Agee CRT Neutral to Buy $96.00 to $124.00
2015-03-12 Boost Price Target Argus Buy $103.00 to $115.00
2015-02-24 Reiterated Rating Deutsche Bank Buy $111.00
2015-02-23 Set Price Target Credit Suisse Buy $112.00
2015-02-04 Reiterated Rating Oppenheimer Hold
2015-02-04 Set Price Target Deutsche Bank Buy $104.00 to $106.00
2015-02-03 Boost Price Target FBR & Co. Outperform $99.00 to $105.00
2015-01-20 Boost Price Target Jefferies Group Buy $103.00 to $106.00
2015-01-20 Boost Price Target Argus Buy $95.00 to $103.00
2015-01-08 Boost Price Target Barclays Overweight $96.00 to $104.00
2015-01-06 Reiterated Rating Deutsche Bank Buy $94.00 to $103.00
2014-12-22 Reiterated Rating Oppenheimer Hold
2014-12-12 Reiterated FBR Capital Outperform $93 to $99
2014-12-12 Boost Price Target Credit Suisse $103.00
2014-12-12 Reiterated Rating Citigroup Inc. Hold $78.00 to $88.00
2014-12-12 Reiterated Rating Jefferies Group Buy $99.00 to $103.00
2014-12-12 Boost Price Target Deutsche Bank Buy $88.00 to $94.00
2014-12-12 Boost Price Target Stifel Nicolaus Buy $90.00 to $100.00
2014-12-12 Boost Price Target FBR & Co. Outperform $93.00 to $99.00
2014-11-18 Reiterated Rating Bank of America Hold $86.00 to $92.00
2014-11-10 Reiterated Rating Jefferies Group Buy $90.00 to $99.00
2014-10-29 Reiterated Rating Deutsche Bank Buy $92.00 to $88.00
2014-10-29 Reiterated Rating Citigroup Inc. Neutral $73.00 to $78.00
2014-10-29 Reiterated Rating Barclays Overweight $95.00 to $96.00
2014-10-03 Upgrade Argus Hold to Buy $95.00
2014-09-22 Downgrade Bank of America Buy to Neutral
2014-08-07 Downgrade Goldman Sachs Buy to Neutral $94.00 to $88.00
2014-08-07 Downgrade Goldman Sachs Group Inc. Buy to Neutral $94.00 to $88.00
2014-07-31 Boost Price Target Leerink Swann Outperform $83.00 to $90.00
2014-07-30 Reiterated Rating Barclays Overweight $87.00 to $95.00
2014-07-29 Boost Price Target FBR & Co. Outperform $80.00 to $93.00
2014-07-16 Reiterated Rating Deutsche Bank Buy $85.00 to $92.00
2014-07-14 Boost Price Target Susquehanna $90.00 to $95.00
2014-07-10 Reiterated Rating Jefferies Group Buy $89.00 to $94.00
2014-06-27 Initiated Coverage Sterne Agee CRT Neutral $87.00
2014-06-18 Reiterated Rating JPMorgan Chase & Co. Overweight $81.00 to $82.00
2014-06-03 Reiterated Rating JPMorgan Chase & Co. Overweight $78.00 to $81.00
2014-06-02 Boost Price Target Cantor Fitzgerald Hold $75.00 to $85.00
2014-05-30 Boost Price Target Cowen and Company $76.00 to $87.00
2014-05-13 Reiterated Rating Morgan Stanley Overweight $83.00
2014-04-25 Boost Price Target Barclays Overweight $80.00 to $87.00
2014-04-25 Boost Price Target Susquehanna $85.00 to $90.00
2014-04-25 Downgrade Citigroup Inc. Buy to Neutral $73.00
2014-04-25 Boost Price Target Jefferies Group $87.00 to $89.00
2014-04-10 Boost Price Target Susquehanna Positive $80.00 to $85.00
2014-04-03 Boost Price Target Deutsche Bank Buy $76.00 to $84.00
2014-03-12 Reiterated UBS Buy $82 to $86
2014-03-07 Boost Price Target Jefferies Group Buy $87.00
2014-02-10 Boost Price Target Cantor Fitzgerald $75.00
2014-02-06 Upgrade Leerink Swann Market Perform to Outperform
2014-01-09 Upgrade Credit Suisse Neutral to Outperform $69.00 to $83.00
2014-01-08 Boost Price Target Barclays Overweight $75.00 to $80.00
2013-12-13 Boost Price Target FBR & Co. Outperform $71.00 to $75.00
2013-12-13 Reiterated Rating Morgan Stanley Overweight $83.00
2013-11-25 Reiterated UBS Buy $76 to $82
2013-11-21 Initiated Coverage Morgan Stanley Overweight $83.00
2013-11-19 Initiated Coverage Leerink Swann Outperform to Market Perform $72.00
2013-11-13 Initiated Coverage FBR & Co. Outperform
2013-11-05 Downgrade Monness Crespi & Hardt Buy to Neutral
2013-10-30 Lower Price Target Deutsche Bank Buy $79.00 to $73.00
2013-10-30 Lower Price Target JPMorgan Chase & Co. Overweight $74.00 to $71.00
2013-10-30 Lower Price Target Barclays Overweight $78.00 to $75.00
2013-10-30 Lower Price Target BMO Capital Markets Outperform $70.00
2013-10-16 Boost Price Target Deutsche Bank Buy $72.00 to $79.00
2013-10-09 Reiterated Rating Susquehanna Positive $74.00 to $76.00
2013-09-24 Boost Price Target JPMorgan Chase & Co. Overweight $71.00 to $74.00
2013-09-17 Reiterated UBS Buy $73 to $76
2013-09-17 Reiterated Rating Cantor Fitzgerald Hold $65.00
2013-08-06 Reiterated Cantor Fitzgerald Hold $60 to $65
2013-08-01 Reiterated UBS Buy $68 to $73
2013-07-23 Initiated Stifel Buy $80
2013-07-16 Reiterated Deutsche Bank Buy $68 to $72
2013-05-01 Reiterated Cantor Fitzgerald Hold $55 to $60
2013-05-01 Reiterated Barclays Overweight $57 to $69
2013-04-02 Reiterated Deutsche Bank Buy $55 to $60
2016-07-10 Reiterated Rating Credit Suisse Group AG Neutral to Hold
2016-06-29 Reiterated Rating Credit Suisse Hold $120.00
2016-06-29 Reiterated Rating Credit Suisse Group AG Hold $120.00
2016-06-28 Initiated Coverage Wolfe Research Outperform $154.00
2016-06-21 Reiterated Rating Leerink Swann Outperform

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Bertolini Mark T Chairman, CEO and President 32243.79%  (114143) AET / VZ /
Reisman Lonny SVP, Chief Medical Officer 24144.07%  (85470) AET /
Rohan Karen Exec. V.P., Local/Regional Bus 21157.06%  (74896) AET / USB /
Casazza William James Sr. VP & General Counsel 16680.79%  (59050) AET /
GUERTIN SHAWN M Exec. Vice President, CFO 13767.51%  (48737) AET /
HANCOCK ELLEN M 13324.58%  (47169) AET / CL /
SOISTMAN FRANCIS S JR Exec. VP, Government Services 12878.53%  (45590) AET /
COHEN BETSY Z 12153.67%  (43024) AET / FNTC / RAS /
McCarthy Margaret M EVP, Operations & Technology 10994.35%  (38920) AET / FAF /
LOVEMAN GARY W EVP, Healthcare Services Bus. 8881.92%  (31442) AET / COH / CZR / FDX /
Zubretsky Joseph M Sr. EVP, National Businesses 7861.58%  (27830) AET / MOH / THG /
HACKMAN FRANKLIN BARBARA 6876.84%  (24344) AET /
SABATINO THOMAS J JR EVP and General Counsel 6170.06%  (21842) AET / HTZ / IG / WAG /
CLARK FRANK M 4609.04%  (16316) AET / WM /
LUDWIG EDWARD J 3735.88%  (13225) AET / BSX / XYL /
GARTEN JEFFREY E 3110.45%  (11011) AET / KMX /
AGUIRRE FERNANDO 2898.59%  (10261) AET / CQB /
Coye Molly Joel 2309.04%  (8174) AET /
HARRINGTON RICHARD J 2288.14%  (8100) AET / XRX /
Paz Harold L Exec. VP, Chief Medical Off. 1672.88%  (5922) AET / SEM /
NEWHOUSE JOSEPH P 1148.02%  (4064) AET /
Parmeswar Rajan VP/Controller/Chief Acct Off 847.46%  (3000) AET /
Jelinek Richard M EVP, Enterprise Strategy 819.21%  (2900) AET /
SNOWE OLYMPIA J. 401.13%  (1420) AET / SYF / TROW /
Virag Sharon VP, Controller & CAO 39.55%  (140) AES / AET / NEO /

Comments